Regenxbio (RGNX) Receivables (2014 - 2025)

Regenxbio's Receivables history runs 12 years deep, the most recent figure standing at $30.7 million for Q4 2025.

• In Q4 2025, Receivables fell 4.83% year-over-year to $30.7 million; the TTM figure through Dec 2025 stood at $30.7 million (down 4.83% YoY), while the FY2025 annual figure was $30.7 million, down 4.83% from the prior year.
• Receivables was $30.7 million for Q4 2025 at Regenxbio, down from $42.3 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $77.7 million in Q3 2021 to a low of $19.4 million in Q1 2025.
• Historically, Receivables has averaged $37.3 million across 5 years, with a median of $31.4 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Receivables tumbled 66.41% in 2023, then soared 74.5% in 2025.
• A 5-year view of Receivables shows it stood at $35.8 million in 2021, then climbed by 0.03% to $35.8 million in 2022, then dropped by 14.8% to $30.5 million in 2023, then gained by 5.76% to $32.2 million in 2024, then slipped by 4.83% to $30.7 million in 2025.
• The last three Receivables figures came in at $30.7 million (Q4 2025), $42.3 million (Q3 2025), and $21.8 million (Q2 2025), per Business Quant data.